Provided by Tiger Fintech (Singapore) Pte. Ltd.

AlloVir, Inc.

9.65
+0.53005.81%
Post-market: 9.650.00000.00%16:10 EDT
Volume:3.48K
Turnover:33.39K
Market Cap:48.02M
PE:-0.48
High:9.79
Open:9.63
Low:9.46
Close:9.12
Loading ...

Company Profile

Company Name:
AlloVir, Inc.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
8
Office Location:
1100 Winter Street,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Directors

Name
Position
David Hallal
Chief Executive Officer and Director
Vikas Sinha
President, Chief Financial Officer and Director
Ansbert Gadicke
Director
Diana Brainard
Director
Jeffrey S. Bornstein
Director
John Wilson
Director
Juan Vera
Director
Malcolm Brenner
Director
Morana Jovan Embiricos
Director

Shareholders

Name
Position
David Hallal
Chief Executive Officer and Director
Vikas Sinha
President, Chief Financial Officer and Director
Agustin Melian
Chief Medical Officer
Ann Leen
Chief Scientific Officer
Brett Hagen
Chief Accounting Officer
Edward Miller
General Counsel
Ercem Atillasoy
Chief Regulatory and Safety Officer
Jeroen van Beek
Chief Commercial Officer